Refractory myocardial angina and determinants of prognosis

Catheterization and Cardiovascular Interventions

Volumn 75, Issue 6, 2010, Pages 892-894

  Kornowski, Ran ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE MEDICINE; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ANGIOGENIC GENE THERAPY; BYPASS SURGERY; CARDIOLOGIST; CONVENTIONAL ANGIOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG ELUTING STENT; EDITORIAL; EVIDENCE BASED MEDICINE; EXPERIMENTAL THERAPY; FUNCTIONAL RESIDUAL CAPACITY; GOLD STANDARD; HEALTH CARE MANAGEMENT; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; INSTITUTIONAL CARE; MEDICAL CARE; MORTALITY; PALLIATIVE THERAPY; PATIENT COUNSELING; PROGNOSIS; QUALITY OF LIFE INDEX; RISK MANAGEMENT; SPINAL CORD STIMULATION; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ANGINA PECTORIS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; MYOCARDIAL REVASCULARIZATION; PROGNOSIS;

EID: 77951760699     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22583     Document Type: Editorial

References (21)

1. Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG. Direct myocardial revascularization and angiogenesis - how many patients might be eligible? Am J Cardiol 1999;84:598-600.
2. Mukherjee D, Comella K, Bhatt DL, Roe MT, Patel V, Ellis SG. Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. Am Heart J 2001;142:72-74.
3. Jolicoeur EM, Granger CB, Henry TD, Holmes DJ, Pepine CJ, Mark D, Chaitman BR, Gersh BJ, Ohman EM; Working Group Members. Clinical and research issues regarding chronic advanced coronary artery disease: Part I: Contemporary and emerging therapies. Am Heart J 2008;155:418-434.
4. Jolicoeur EM, Ohman EM, Temple R, Stockbridge N, Smith S, Mark D, Califf RM, Henry TD, Chaitman BR, Granger CB; Working Group Members. Clinical and research issues regarding chronic advanced coronary artery disease Part II: Trial design, outcomes, and regulatory issues. Am Heart J 2008;155:435-444.
5. Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, Follath F, Hellemans I, Herlitz J, Lüscher T, Pasic M, Thelle D. The problem of chronic refractory angina; Report from the ESC Joint Study Group on the treatment of refractory angina. Eur Heart J 2002;23:355-370.
6. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, Chamberlain DA; Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. J Am Coll Cardiol 2003;42, 1161-1170.
7. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516.
8. DeJongste MJ, Tio RA, Foreman RD. Chronic therapeutically refractory angina pectoris. Heart 2004;90:225-230.
9. Leong L, Horowitz J, Frenneaux M. Metabolic manipulation in ischemic heart disease, a novel approach to treatment. Eur Heart J 2004;25:634-641.
10. Leon MB, Kornowski R, Downey WE, Weisz G, Baim DS, Bonow RO, Hendel RC, Cohen DJ, Gervino E, Laham R, Lembo NJ, Moses JW, Kuntz RE. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol 2005;46:1812-1819.
11. Fuchs S, Satler LF, Kornowski R, Weisz G, Baffour R, Waksman R, Weissman NJ, Cerqueira M, Leon MB, Epstein SE. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: A feasibility study. J Am Coll Cardiol 2003;41:1721-1724.
12. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Asahara T, Isner JM, Kuntz RE. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-2018.
13. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Silva GV, Mesquita CT, Rossi MI, Belem L, Vaughn WK, Rangel FO, Assad JA, Carvalho AC, Branco RV, Rossi MI, Dohmann HJ, Willerson JT. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004;110(Suppl 1):11213-11218.
14. Carvalho AC, Dutra HS, Dohmann HJ, Silva GV, Belém L, Vivacqua R, Rangel FO, Esporcatte R, Geng YJ, Vaughn WK, Assad JA, Mesquita ET, Willerson JT. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003;107:2294-2302.
15. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER; VIVA Investigators. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-1365.
16. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-793.
17. Kornowski R, Fuchs S, Zafrir N. Refractory myocardial ischemic syndromes: Patients' characterization and treatment goals. Future Cardiol 2005;1:629-635.
18. Williams B, Menon M, Satran D, Hayward D, Hodges JS, Burke N, Johnson RK, Poulose AK, Traverse JH, Henry TD. Patients with coronary artery disease not amenable to traditional revascularization: Prevalence and 3-Year mortality. Catheter Cardiovasc Interv 2010 (in press).
19. Go V, Bhatt MR, Hendel RC. The diagnostic and prognostic value of ECG-gated SPECT myocardial perfusion imaging. J Nucl Med 2004;45:912-921.
20. Gibbons RJ. Myocardial perfusion imaging. Heart 2000;83:355-360.
21. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117: 1283-1291.